Tuberculosis Research and Epidemiology

This study evaluates the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis using beta-lactams and LdtMt2 inhibitors, finding stronger growth suppression with Ldt inhibition.

This study identifies niclosamide as a compound that induces drug tolerance in Mycobacterium tuberculosis by disrupting the pH gradient, revealing a new mechanism for persister cell formation.

The paper uses metabolic tagging to identify surface-associated lipoproteins in mycobacteria, revealing their presence without known transporters.

The paper shows HIV-1 Tat enhances Mtb and Toxoplasma growth by inhibiting clathrin-mediated endocytosis and autophagy through PI(4,5)P2 binding and palmitoylation.

This paper develops a 96-well plate assay to identify anti-TB drugs effective against drug-tolerant Mtb in macrophages, showing host immune stresses can induce tolerance or synergize with certain drugs.

This study identifies PU.1 as a key transcription factor regulating epigenetic responses to Mtb, showing its role in supporting infection and potential as a therapeutic target.

The paper shows that host cell cycle stages influence endocytic capacity and redox states in M. tuberculosis, leading to phenotypic diversity within infected cells.

This study identifies cathepsin Z as a susceptibility factor for tuberculosis severity in both mice and humans, showing its role in disease outcomes through genetic and cellular analyses.

This study improves rifampicin resistance prediction in M. tuberculosis by accounting for resistant subpopulations and compensatory mutations, increasing sensitivity without sacrificing specificity.

This study shows that deleting the ESX-5 secretion system in Mycobacterium tuberculosis reduces ESX-5 substrate secretion, increases ESX-1 substrates, decreases ESX-3 expression, and alters cell morphology and antibiotic susceptibility.

This study shows that z-VAD induces necroptosis in macrophages infected with Mtb, M. kansasii, and R. equi by acting on non-canonical targets, and MLKL deficiency reduces TB pathology in susceptible mice.

The paper develops mRNA-based classifiers using RNA-seq and machine learning to accurately distinguish bTB-positive from bTB-negative cattle and other pathogens.

The paper identifies CD226 as a marker distinguishing effector from dysfunctional CD8+ T cells in Mtb infection and shows its role in costimulating recognition of Mtb-infected macrophages.

This paper introduces a 3D tuberculoma bioplatform for studying tuberculosis biology and high-content screening, showing it can generate structured lesions and be scaled for high-throughput use.

This paper develops a 3D bioplatform to screen host-directed therapeutics for tuberculosis, identifying compounds that reduce mycobacterial burdens and granuloma lesions.

This study identifies Rv3204 as an m4C DNA methyltransferase essential for Mycobacterium tuberculosis survival under oxidative stress, showing its role in ROS homeostasis and antibiotic susceptibility.

This study shows that c-Myc inhibition enhances macrophage antimycobacterial activity and reduces MTB persistence in both in vitro and in vivo models.

This study investigates the K+/Na+ dependent oligomerization and DNA binding mechanism of MoyR, a GntR family regulator in M. tuberculosis, revealing its role in gene regulation and potential as a drug target.

This study performs proteomic analysis of Mycobacterium tuberculosis lacking Rv0148, identifying changes in protein expression and pathways related to stress response, cell wall, and metabolism.

This study identifies 30 Mtb enzymes inhibited by meropenem, revealing polypharmacology beyond known cell wall targets.

This study shows NRF2 inhibits MHC II expression in alveolar macrophages during Mtb infection, impairing CD4+ T cell activation and host immunity.

The paper detects Mtb transcripts in human granuloma cells using scRNA-seq, finding sequence variations suggesting potential adaptive mechanisms.

This study identifies compounds from Berberis holstii that inhibit Mycobacterium tuberculosis efflux pumps, showing synergistic effects with spectinomycin.

This study identifies PPE2 as a Mycobacterium tuberculosis protein that induces insulin resistance and hyperglycemia by altering adipose tissue function and metabolism.

The paper shows pyrimethamine, an FDA-approved drug, reduces vascular permeability and mycobacterial burden in a zebrafish infection model by inhibiting bacterial dihydrofolate reductase and restoring vascular barrier function.

The paper shows that epistatic interactions between RpoB and GyrA mutations in Mycobacterium tuberculosis can lead to high-fitness double-resistant strains, which are prevalent in clinical isolates.

This study evaluates the forgiveness of TB drug combinations using a mouse model, finding BPaMZ is more forgiving of missed doses than RHZE/RH.

The paper uses single-cell RNA sequencing to analyze lung granulomas in M. tuberculosis-infected mice, identifying novel macrophage subtypes and markers associated with TB pathogenesis.

This study identifies Rv1250 as a multidrug efflux pump in Mycobacterium tuberculosis that enhances drug resistance by facilitating drug extrusion and biofilm formation.

This study identifies USP15 as a negative regulator of autophagy and macrophage immunity to Mycobacterium tuberculosis, showing that its inhibition reduces bacterial burden.